GAL3ST1 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q99999 |
---|---|
Clone Names | 90504060 |
Gene ID | 9514 |
---|---|
Other Names | Galactosylceramide sulfotransferase, GalCer sulfotransferase, 3'-phosphoadenosine-5'-phosphosulfate:GalCer sulfotransferase, 3'-phosphoadenylylsulfate:galactosylceramide 3'-sulfotransferase, Cerebroside sulfotransferase, GAL3ST1, CST |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP8884c was selected from the Center region of human GAL3ST1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | GAL3ST1 (HGNC:24240) |
---|---|
Function | Catalyzes the transfer of a sulfate group to position 3 of non-reducing beta-galactosyl residues in glycerolipids and sphingolipids, therefore participates in the biosynthesis of sulfoglycolipids (PubMed:9030544, PubMed:8830034). Catalyzes the synthesis of galactosylceramide sulfate (sulfatide), a major lipid component of the myelin sheath and of monogalactosylalkylacylglycerol sulfate (seminolipid), present in spermatocytes (PubMed:8830034). Seems to prefer beta-glycosides at the non-reducing termini of sugar chains attached to a lipid moiety (PubMed:8830034). Also acts on lactosylceramide, galactosyl 1-alkyl-2-sn-glycerol and galactosyl diacylglycerol (in vitro) (PubMed:8830034). |
Cellular Location | Golgi apparatus membrane; Single- pass type II membrane protein |
Tissue Location | Expressed in kidney proximal tubule, gastric mucosa and adenocarcinoma (PubMed:9030544, PubMed:10785389). Highly expressed in renal cell carcinoma cell lines (PubMed:9030544, PubMed:8830034) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Sulfonation, an important step in the metabolism of many drugs, xenobiotics, hormones, and neurotransmitters, is catalyzed by sulfotransferases. GAL3ST1 is galactosylceramide sulfotransferase which catalyzes the conversion between 3'-phosphoadenylylsulfate + a galactosylceramide to adenosine 3',5'-bisphosphate + galactosylceramide sulfate. Activity of this sulfotransferase is enhanced in renal cell carcinoma.
References
Siegrist,H.P., et.al., Biochim. Biophys. Acta 489 (1), 58-63 (1977)Stein,C., et.al., J. Biol. Chem. 264 (2), 1252-1259 (1989)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.